<DOC>
	<DOCNO>NCT02854423</DOCNO>
	<brief_summary>Both biodegradable polymer-based biolimus-eluting stent ( BP-BES ) durable polymer-based everolimus-eluting stent ( DP-EES ) show improve long-term clinical outcome compare early generation DES . BP-BES DP-EES directly compare 2 randomized trial , show difference two device all-comer patient long-term follow-up . It unknown whether result consistent real-world patient diabetes mellitus long-term follow-up . To evaluate safety efficacy profile biodegradable polymer-coated biolimus-eluting stent ( BP-BES ) compare durable polymer-coated everolimus-eluting stent ( DP-EES ) patient diabetes mellitus long-term follow-up . Consecutive diabetic patient undergo percutaneous coronary intervention BP-BES DP-EES implantation include multicenter registry January 2007 May 2012 . Long-term clinical outcome BP-BES DP-EES compare use propensity score matching . The pre-specified primary endpoint occurrence major cardiac adverse event ( MACE ) - composite all-cause death , myocardial infarction ( MI ) target-vessel revascularization ( TVR ) . Secondary endpoint individual component primary endpoint well definite stent thrombosis ( ST ) .</brief_summary>
	<brief_title>Comparison Biodegradable Polymer v Durable-polymer Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>age &gt; 18 year diabetes mellitus percutaneous coronary intervention biolimus elute stent everolimus elute stent implantation sign informed consent plan procedure require antiplatelet therapy withdrawal within 12 month index coronary angioplasty patient contraindication dual antiplatelet therapy ( aspirin plus ticlopidine clopidogrel ) know allergy stent drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>